Albatira, Myline T.

HRN: 21-24-71  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/18/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/18/2022
05/24/2022
IVT
500mg 7 Doses
Q8
S/P Cesarean Section
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: